The treatment of irritable bowel syndrome

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 4, 2009, Pages 221-238

  Lacy, Brian E ^a   Weiser, Kirsten ^a   Lee, Ryan De ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Abdominal pain; Alosetron; Bloating; Constipation; Diarrhea; Irritable bowel syndrome; Lubiprostone; Probiotics; Tegaserod; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DICYCLOVERINE; DOXEPIN; DULOXETINE; FLUOXETINE; GABAPENTIN; GERMANIUM; IMIPRAMINE; LACTULOSE; LAVENDER OIL; MACROGOL; MAGNESIUM HYDROXIDE; MAGNESIUM SULFATE; NORTRIPTYLINE; PAROXETINE; PEPPERMINT; PLACEBO; PREGABALIN; PROBIOTIC AGENT; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUPUNCTURE; ALTERNATIVE MEDICINE; BIFIDOBACTERIUM LONGUM INFANTIS; BLADDER AND BOWEL MANAGEMENT; BLOATING; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRY EYE; EDUCATION; FIBER; HUMAN; INTERVENTION STUDY; IRRITABLE COLON; LIFESTYLE MODIFICATION; MEDICAL LITERATURE; NEUROPATHIC PAIN; NONHUMAN; NUTRITIONAL ASSESSMENT; PALLIATIVE THERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VISION; XEROSTOMIA;

EID: 77951674827     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09104794     Document Type: Review

References (122)

1. Agrawal, A. and Whorwell, P.J. (2008) Review article: abdominal bloating and distention in functional gastrointestinal disorders - epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther 27: 2-10.
2. American Gastroenterological Association ( 2001) The Burden of Gastrointestinal Diseases. Bethesda: American Gastroenterological Association.
3. Andresen, V., Camilleri, M., Busciglio, I.A., Grudell, A., Burton, D., McKinzie, S. et al. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761-768.
4. Barret, J.S. and Gibson, P.R. (2007) Clinical ramifications of malabsorption of fructose and other short-chain carbohydrates. Practical Gastroenterol 31: 51-65.
5. Bohmer, C.J. and Tuynman, H.A. (2001) The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5 year follow-up study. Eur J Gastroenterol Hepatol 13: 941-944.
6. Brandt, L.J., Bjorkman, D., Fennerty, M.B., Locke, G.R., Olden, K., Peterson, W. et al. (2002) Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97: S7-S26.
7. Bratten, J.R., Spanier, J. and Jones, M.P. (2008) Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 103: 958-963.
8. Bray, G.A., Nielsen, S. and Popkin, B. (2004) Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J of Clin Nutr 79: 537-543.
9. Brennan B. (2003) An open-label study of duloxetine for the treatment of irritable bowel syndrome. Available at: clinicaltrials.gov/ct2/show/recordNCT00401258.
10. Camilleri, M., Chey, W.Y., Mayer, E.A., Northcutt, A.R., Heath, A., Dukes, G.E. et al. (2001) A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Int Med 161: 1733-1740.
11. Camilleri, M., Kerstens, R., Rykx, A. and Vandeplassche, L. (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344-2354.
12. Cann, P.A., Read, N.W. and Holdsworth, C.D. (1984) What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 25: 168-173.
13. Cann, P.A., Read, N.W., Holdsworth, C.D. and Barends, D. (1984) Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 29: 239-247.
14. Cappello, G., Spezzaferro, M., Grossi, L., Manzoli, L. and Marzio, L. (2007) Peppermint oil in the treatment of irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. Dig Liver Dis 39: 530-536.
15. Cash, B.D. and Lacy, B.E. (2006) Systematic review: FDA approved prescription medications for adults with constipation. Gastroenterol Hepatol 10: 736-749.
16. Cash, B.D., Lee, D., Riddle, M., Truesdale, M., Dykes, C., Saad, R. et al. (2008) President's Plenary Session: Yield of diagnostic testing in patients with suspected irritable bowel syndrome (IBS): A prospective US multicenter trial. Am J Gastroenterol 103: S462.
17. Cash, B.D., Schoenfeld, P. and Chey, W.D. (2002) The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 97: 2812-2819.
18. Chang, L., Chey, W.D., Harris, L., Olden, K., Surawicz, C. and Schoenfeld, P. (2006) Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101: 1069-1079.
19. Chey, W., Talley, N., Lembo, A., Yu, J. and Bortey, E. (2008) Rifaximin significantly improves quality of life versus placebo in patients with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 103: 1182.
20. Chiarioni, G. and Whitehead, W.E. (2008) The role of biofeedback in the treatment of gastrointestinal disorders. Nat Clin Pract Gastroenterol Hepatol 5: 371-382.
21. Choi, Y.K., Johlin, F.C. Jr, Summers, R.W. et al. (2003) Fructose intolerance: an under-recognized problem. Am J Gastroenterol 98: 1348-1353.
22. Choi, Y.K., Kraft, N., Zimmerman, B., Jackson, M. and Rao, S.S. (2008) Fructose intolerance in IBS and utility of fructose restricted diet. J Clin Gastroenterol 42: 233-238.
23. Clouse, R.E. (2003) Antidepressants for irritable bowel syndrome. Gut 52: 598-599.
24. Coremans, G., Clouse, R.E., Carter, F., Krause, G., Catas, S. and Steinborn, C. (2004) Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance. Gastroenterology 126: 643.
25. Creed, F., Ratcliffe, J., Fernandez, L., Tomenson, B., Palmer, S., Rigby, C. et al. (2001) Health-related qualify of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 134: 860-868.
26. Cuppoletti, J., Malinowska, D.H., Tewari, K.P., Li, Q.J., Sherry, A.M., Patchen, M.L. et al. (2004) SPI-0211 activates T 84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 287: 1183.
27. Currie, M.G., Fok, K.F., Kato, J., Moore, R.J., Hamra, F.K., Duffin, K.L. et al. (1992) Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci 89: 947-951.
28. Davis, K., Philpott, S., Kumar, D. and Mendall, M. (2006) Randomized double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 60: 1080-1086.
29. Di Stefano, M., Strocchi, A., Malservisi, S., Veneto, G., Ferrieri, A. and Corazza, G.R. (2000) Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 14: 1001-1008.
30. Di Stefano, M., Miceli, E., Missanelli, A., Mazzocchi, S., Tana, P. and Corazza G.R. (2006) Role of colonic fermentation in the perception of colonic distention in irritable bowel syndrome and functional bloating. Clin Gastroenterol and Hepatol 4: 1242-1247.
31. Drossman, D.A., Li, Z., Andruzzi, E., Temple, R.D., Talley, N.J., Thompson, W.G. et al. (1993) US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 38: 1569-1580.
32. Drossman, D.A., Camilleri, M., Mayer, E.A. and Whitehead, W.E. (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123: 2108-2131.
33. Drossman, D.A., Toner, B.B., Whitehead, W.E., Diamant, N.E., Dalton, C.B., Duncan, S. et al. (2003) Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125: 19-31.
34. Drossman, D.A., Chey, W.D., Johanson, J.F., Fass, R., Scott, C., Panas, R. et al. (2007) Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterology 132: 2586-2587.
35. Efskind, P.S., Bernklev, T. and Vatn, M.H. (1996) A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 31: 463-468.
36. Emmanuel, A.V., Roy, A.J., Nicholls, T.J. and Kamm, M.A. (2002) Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 16: 1347-1356.
37. Evans, B.W., Clark, W.K., Moore, D.J. and Whorwell, P.J. (2007) Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev CD003960.
38. Farup, P.G., Monsbakken, K.W. and Vandvik, P.O. (2004) Lactose malabsorption in a population with irritable bowel syndrome: prevalence and symptoms. A case-control study. Scand J Gastroenterol 39: 645-649.
39. Ford, A., Brandt, L., Foxx-Orenstein, A., Chey, W., Schoenfeld, P. and Moayyedi, P. (2008 d) Efficacy of 5HT3-antagonists in non-constipation predominant irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 103: S477.
40. Ford, A.C., Talley, N.J., Spiegel, B.M., Foxx-Orenstein, A.E., Schiller, L., Quigley, E.M. et al. (2008 a) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337: a2313.
41. Ford, A.C., Talley, N.J., Schoenfeld, P.S. Quigley, E.M. and Moayyedi, P. (2008 b) Efficacy of antidepressants and Psychological Therapies in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. doi:10.1136/gut.2008.163162.
42. Ford, A., Talley, N., Spiegel, B., Foxx-Orenstein, A., Schiller, L. and Quigley, E. (2008 c) Efficacy of fiber in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 103: S459.
43. Frank, L., Kleinman, L., Rentz, A., Ciesla, G., Kim, J.J. and Zacker, C. (2002) Health-related quality of life associated with irritable bowel syndrome: Comparison with other chronic diseases. Clin Ther 24: 675-689.
44. Gralnek, I.M., Hays, R.D., Kilbourne, A., Naliboff, B. and Mayer, E.A. (2000) The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119: 654-660.
45. Greenbaum, D.S., Mayle, J.E., Vanegeren, L.E., Jerome, J.A., Mayor, J.W., Greenbaum, R.B. et al. (1987) Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 32: 257-266.
46. Guandalini, S., Chiaro, A., Labalestra, V., Gopalan, S., Romano, C. and Canani, R.B. (2008) Efficacy of the probiotic Vsl#3 in children with irritable bowel syndrome. An international, randomized, placebo-controlled, double-blind, cross-over trial. Am J Gastroenterol 103: A1342.
47. Hebden, J.M., Blackshaw, E., D'Amato, M., Perkins, A.C. and Spiller, R.C. (2002) Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol 97: 2315-2320.
48. Higgins, P.D.R., Davis, K.J. and Laine, L. (2004) The epidemiology of ischemic colitis. Aliment Pharmacol Ther 19: 729-738.
49. Houghton, L.A., Foster, J.M. and Whorwell, P.J. (2000) Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 14: 775-782.
50. Houghton, L.A., Fell, C., Whorwell, P.J., Jones, I., Sudworth, D.P. and Gale, J.D. (2007) Effect of a second generation α2δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56: 1218-1225.
51. Hovdenak, N. (1987) Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 130: 81-84.
52. Jackson, J.L., O'Malley, P.G., Tomkins, G., Balden, E., Santoro, J. and Kroenke, K. (2000) Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 108: 65-72.
53. Jailwala, J., Imperiale, T.F. and Kroenke, K. (2000) Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 133: 136-147.
54. Jalihal, A. and Kurian, G. (1990) Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol 5: 507-513.
55. Jiang, Z.D. and Du Pont, H.L. (2005) Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 51: 67-72.
56. Johanson, J.F., Panas, R., Holland, P.C. and Ueno, R. (2006) A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (IBS-C). Gastroenterology 130: A25.
57. Jolley, J. (2008) Efficacy of Rifaximin for the treatment of symptoms associated with irritable bowel syndrome. Am J Gastroenterol 103: A1180.
58. Kellow, J., Lee, O.Y., Chang, F.Y., Thongsawat, S., Mazlam, M.Z., Yuen, H. et al. (2003) An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 52: 671-676.
59. Kettell, J., Jones, R. and Lydeard, S. (1992) Reasons for consultation in irritable bowel syndrome: Symptoms and patient characteristics. Br J Gen Pract 42: 459-461.
60. Khoshoo, V., Armstead, C. and Landry, L. (2006) Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 23: 191-196.
61. Kim, H.J., Camilleri, M., McKinzie, S., Lempke, M.B., Burton, D.D., Thomforde, G.M. et al. (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17: 895-904.
62. Kim, H.J., Vazquez Roque, M.I., Camilleri, M., Stephens, D., Burton, D.D., Baxter, K. et al. (2005) A randomized controlled trial of probiotic comination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17: 687-696.
63. Kuiken, S.D., Tytgat, G.N. and Boeckxstaens, G.E. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome; a double-blind, randomized, placebo-controlled study. Clin Gastroenterol Hepat 3: 219-228.
64. Lacy, B.E. and de Lee, R. (2005) Irritable bowel syndrome: A syndrome in evolution. J Clin Gastroenterol 39: S230-S242
65. Lacy, B.E. and Levy, L.C. (2008) Lubiprostone: a novel treatment for chronic constipation. Clin Inter Aging 3: 357-364.
66. Lacy, B.E., Rosemore, J., Robertson, D., Corbin, D.A., Grau, M. and Crowell, M.D. (2006) Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 41: 892-902.
67. Lacy, B.E. and Yu, S. (2002) Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol 34: 27-33.
68. Lavo, B., Stenstam, M. and Nielsen, A.L. (1987) Loperamide in treatment of irritable bowel syndrome - a double-blind, placebo controlled study. Scand J Gastroenterol 130: 77-80.
69. Lee, K.J., Kim, J.H. and Cho, S.W. (2005) Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea predominant irritable bowel syndrome. Aliment Pharmacol Ther 22: 981-988.
70. Lembo, T., Wright, R.A., Bagby, B., Decker, C., Gordon, S., Jhingran, P. et al. (2001) Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96: 2662-2670.
71. Lembo, A., Johnston, J.M., MacDougall, J.E., Kurtz, C.B., Drossman, D.A., Jeglinski, B.I. et al. (2008) Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: data from a large four-week, randomized, double-blind, placebo-controlled study. Gastroenterology Oral Presentation, Digestive Disease Week, San Diego, CA from May 17 - May 22.
72. Lembo, A., Zakko, S.F., Ferreira, N.F., Ringel, Y., Bortey, E., Courtney, K. et al. (2008) Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 134: A545.
73. Lesbros-Pantoflickova, D., Michetti, P., Fried, M., Beglinger, C. and Blum, A.L. (2004) Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 20: 1253-1269.
74. Leventer, S.M., Raudibaugh, K., Frissora, C.L., Kassem, N., Keogh, J.C., Phillips, J. et al. (2008) Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 27: 197-206.
75. Lim, B., Mannheimer, E., Lao, L., Ziea, E., Wisniewski, J., Liu, J. et al. (2006) Acupuncture for treatment of irritable bowel syndrome. Cochrane Data Base Syst Review CD0055111.
76. Liu, C. and Feekery, C. (2001) Can asthma education improve clinical outcomes? An evaluation of a pediatric asthma education program. J Asthma 38: 269-278.
77. Longstreth, G.F., Fox, D.D., Youkeles, L., Forsythe, A.B. and Wolochow, D.A. (1981) Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med 95: 53-56.
78. Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F. and Spiller, R.C. (2006) Functional bowel disorders. Gastroenterology 130: 1480-1491.
79. Malagelada, J.-R. (2002) Sensation and gas dynamics in functional gastrointestinal disorders. Gut 51: i72-i75.
80. Manning, A.P., Heaton, K.W. and Harvey, R.F. (1977) Wheat fibre and irritable bowel syndrome. A controlled trial. Lancet 2: 417-418.
81. Masand, P.S., Gupta, S., Schwartz, T.L., Virk, S., Lockwood, K., Hameed, A. et al. (2002) Paroxetine in patients with irritable bowel syndrome; a pilot open-label study. Primary Care Compan J Clinical Psych 4: 12-16.
82. Mayer, E.A., Berman, S., Derbyshire, S.W., Suyenobu, B., Chang, L., Fitzgerald, L. et al. (2002) The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16: 1357-1366.
83. Morisky, D.E., Levine, D.M., Green, L.W., Russell, R.P., Smith, C., Benson, P. et al. (1980) The relative impact of health education for low- and high-risk patients with hypertension. Prev Med 9: 550-558.
84. Myren, J., Groth, H., Larssen, S.E. and Larsen, S. (1982) The effect of trimipramine in patients with the irritable bowel syndrome. A double blind study. Scand J Gastroenterol 17: 871-875.
85. Myren, J., Lovland, B., Larssen, S.E. and Larsen, S. (1984) A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 19: 835-843.
86. Müller-Lissner, S., Fumagalli, I., Bardhan, K.D., Pace, F., Pecher, E., Nault, B. et al. (2001) Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, constipation. Aliment Pharmacol Ther 15: 1655-1666.
87. Niaz, S.K., Sandrasegaran, K., Renny, F.H. and Jones, B.J. (1997) Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 31: 53-56.
88. Novick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G. et al. (2002) A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 16: 1877-1888.
89. Nyhlin, H., Bang, C., Elsborg, L., Silvennoinen, J., Holme, I., Rüegg, P. et al. (2004) A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 39: 119-126.
90. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K. et al. (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom response and relationship to cytokine profiles. Gastroenterology 128: 541-551.
91. Ooms, L.A., Degryse, A.D. and Janssen, P.A. (1984) Mechanisms of action of loperamide. Scand J Gastroenterol 96(Suppl.): 145-155.
92. Page, J.G. and Dirnberger, G.M. (1981) Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 3: 153-156.
93. Pimentel, M., Chow, E.J. and Lin, H.C. (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: 3503-3506.
94. Pimentel, M., Park, S., Mirocha, J., Kane, S.V. and Kong, Y. (2006) The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome- a randomized trial. Ann Intern Med 145: 557-563.
95. Pimentel, M., Chow, E.J. and Lin, H.C. (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: 412-419.
96. Posserud, I., Stotzer, P.O., Björnsson, E.S., Abrahamsson, H. and Simrén, M. (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: 802-808.
97. Poynard, T., Regimbeau, C. and Benhamou, Y. (2001) Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 15: 355-361.
98. Prior, A. and Whorwell, P.J. (1987) Double-blind study of ispaghula in irritable bowel syndrome. Gut 28: 1510-1513.
99. Quigley, E.M., Devane, J., Young, D. and Butler, J. (2007) A randomized, double-blind, placebo-controlled study of r-verapamil in non-constipated irritable bowel syndrome. Am J Gastroenterol 104: S502.
100. Rajagopalan, M., Kurian, G. and John, J. (1998) Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 13: 738-741.
101. Ravnefjord, A., Brusberg, M., Larsson, H., Lindström, E. and Martínez, V. (2008) Effects of pregabalin on visceral pain responses and colonic compliance in rats. Brit J Pharm 155: 407-416.
102. Ritchie, J. (1973) Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14: 125-132.
103. Saito, Y.A., Prather, C.M., van Dyke, C.T., Fett, S., Zinsmeister, A.R. and Locke 3rd, G.R. (2004) Effects of multidisciplinary education on outcomes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2: 576-584.
104. Saito-Loftus, Y., Brantner, T., Zimmerman, J., Talley, N. and Murray, J. (2008) The prevalence of positive serologic tests for celiac sprue does not differ between irritable bowel syndrome (IBS) patients compared with controls. Am J Gastroenterol 103: P687.
105. Sandler, R.S., Everhart, J.E., Donowitz, M., Adams, E., Cronin, K. and Goodman, C. (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500-1511.
106. Serra, J., Azpiroz, F. and Malagelada, J.-R. (2001) Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 48: 14-19.
107. Sharara, A.I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S. and Elhajj, I. (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326-333.
108. Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L. and Hungin, P. (2007) Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56: 1770-1798.
109. Tabas, G., Beaves, M., Wang, J., Friday, P., Mardini, H. and Arnold, G. (2004) Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet. Am J Gastroenterol 99: 914-920.
110. Tack, J., Broekaert, D., Fischler, B., van Oudenhove, L., Gevers, A.M. and Janssens, J. (2006) A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55: 1095-1103.
111. Talley, N.J., Zinsmeister, A.R., van Dyke, C. and Melton, L.J. (1991) Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101: 927-934.
112. Talley, N.J., Gabriel, S.E., Harmsen, W.S., Zinmeister, A.R. and Envas, R.W. (1995) Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 109: 1736-1741.
113. Talley, N.J., Kellow, J.E., Boyce, P., Tennant, C., Huskic, S. and Jones, M. (2008) Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double blind, randomized, placebo-controlled trial. Dig Dis Sci 53: 108-115.
114. Toskes, P.P., Connery, K.L. and Ritchey, T.W. (1993) Calcium polycarbophil compared with placebo in the irritable bowel syndrome. Aliment Pharmacol Ther 7: 87-92.
115. Tremolattera, F., Villoria, A., Azpiroz, F., Serra, J., Aguadé, S. and Malagelada, J.R. (2006) Impaired viscersomatic reflexes and abdominal-wall dystony associated with bloating. Gastroenterology 130: 1062-1068.
116. Vahedi, H., Merat, S., Rashidioon, A., Ghoddoosi, A. and Malekzadeh, R. (2005) The effect of fluoxetine on patients with pain and constipation predominant irritable bowel syndrome; a double-blind, randomized-controlled study. Aliment Pharmacol Ther 22: 381-385.
117. Vahedi, H., Merat, S., Momtahen, S. et al. (2008) Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 27: 678-684.
118. Vejdani, R., Shalmani, H.R., Mir-Fattahi, M., Sajed-Nia, F., Abdollahi, M., Zali, M.R. et al. (2006) The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study, Dig Dis Sci 51 (8): 1501-7.
119. Vinicor, F., Cohen, S.J., Mazzuca, S.A., Moorman, N., Wheeler, M., Kuebler, T. et al. (1987) DIABEDS: a randomized trial of the effects of physician and/or patient education on diabetes patient outcomes. J Chronic Dis 40: 345-356.
120. Whitehead, W.E., Holtkotter, B., Enck, P., Hoelzl, R., Holmes, K.D., Anthony, J. et al. (1990) Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 98: 1187-1192.
121. Whorwell, P.J., Altringer, L., More, J., Bond, Y., Charbonneau, D., O'Mahony, L. et al. ( 2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35643 in women with irritable bowel syndrome. Am J Gastroenterol 101: 1581-1590.
122. Wiffen, P., Collins, S., McQuay, H., Carroll, D., Jadad, A. and Moore, A. (2000) Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev CD001133.